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Abstract
Background: Genomic medicine is rapidly evolving, particularly in the domain
of reproduction. Population carrier screening for a range of disorders is becoming
possible using whole genome/exome sequencing. However, very little is known
about the views of genetically disabled adults toward selective reproduction.
Methods: Forty‐three in‐depth qualitative interviews were carried out with adults liv-
ing with different types of genetic condition, recruited through support groups and
clinics. Interviews covered participants’ experiences of their condition and their views
toward genetic intervention in reproduction. Thematic analysis of the data using
NVivo 11 was undertaken, and participants were assigned categories as either
supporting, not‐supporting, or having ambivalent views toward selective reproduction.
Results: The majority of participants (65%) expressed either disapproval of, or held
ambivalent views toward, selective reproduction. Key reasons for non‐support
included regarding genetic impairment as part of personal identity and the prioritiza-
tion of social and environmental barrier removal. Key reasons for support of selective
reproduction included negative and externalizing attitudes toward genetic impairment
and a belief in the importance of informed reproductive decision‐making.
Conclusion: The degree to which participants identified with their impairment,
more so than how they valued it, was significant in determining attitudes toward
selective reproduction. Those who supported genetic screening viewed their
impairment as separate to themselves, while participants who considered their
impairment as integral to their identity were most likely to report ambivalent or
negative attitudes. Policymakers and stakeholders considering the role of genetic
carrier screening panels might usefully engage with adults affected by heritable
disease as well as disability identity politics when considering the acceptability
and social impact of genetic screening programs.
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1 | INTRODUCTION
Genomic medicine is a rapidly advancing field, and
nowhere more markedly than within the domain of
reproduction. Technologies such as whole genome
sequencing (capable of screening individuals and fetuses
for large panels of genetic disorders simultaneously) and
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noninvasive prenatal testing (NIPT, which renders the pro-
cess of obtaining samples for such genomic screening both
safer and more efficient than ever before) are increasingly
being subsumed within mainstream health care (e.g., the
100,000 Genomes Project) bringing with them significant
social and ethical challenges (Nuffield Council on
Bioethics, 2018). Indeed, through the capacity to identify
genetic carriers (i.e., people who may transmit a genetic
disorder but who do not have one themselves) for increas-
ingly large panels of genetic disorders (Plantinga et al,
2016), ideas about “responsible” reproductive decision‐
making are, in tandem, rapidly evolving.
Currently, the birth of a child with an inherited genetic
disorder is most commonly an unanticipated event. As
such, reproductive decisions regarding subsequent pregnan-
cies for the carrier parents are typically made in the context
of their first‐hand knowledge about that particular condition
(McClaren et al, 2010). Research has consistently demon-
strated the significance and value of this “experiential
knowledge” to families living with genetic disease in the
formulation of their subsequent reproductive attitudes and
decisions (Clarke, 2016; Dudding, Wilcken, Burgess, Ham-
bly, & Turner, 2000). The introduction of preconception
genetic screening, through the use of whole genome
sequencing (WGS) or whole exome sequencing (WES),
however, has the capacity to fundamentally alter this typi-
cal pathway through reprogenetic decision‐making (Plan-
tinga et al, 2016). By alerting carrier parents to the
possibility of their child having a genetic disease before
that child is even conceived, such parents will, in the
future, have the opportunity (not currently afforded to them
within NHS care) of avoiding having a genetically
impaired child altogether. This marks a significant shift.
Reproductive decision‐making associated with rare and
inheritable genetic disorders will no longer be the exclusive
domain of people already familiar, or firmly embedded
within, the realities of life with that condition. Rather, they
will increasingly be made by members of the general pub-
lic—the vast majority of whom will never have experi-
enced, or even heard of the conditions before (Ioannou,
Delatycki, Massie, Hodgson, & Lewis, 2015; McClaren,
Delatycki, Collins, Metcalfe, & Aitken, 2008).
These changes, suggested by early population screens,
are particularly significant for genetically disabled people.
While disabled people and their families have long been
described as the “best experts” on the condition(s) they live
with (Petersen, 2006), the lack of open dialogue with such
families and individuals around genetic interventions in
reproduction is particularly striking, being highlighted as a
significant concern in the Nuffield Council's ethical review
of noninvasive prenatal testing (Nuffield Council on
Bioethics, 2017). While this lack of inclusion might be jus-
tified on the grounds that already affected families are not
the intended recipients of population‐level genetic screen-
ing programs, there is nevertheless the potential for signifi-
cant impacts for them. Such impacts might include
reductions in peer support (as less children come into the
world with the same disorder), a decline in public funding
into treatments and cures (due to the increased rarity of the
condition), as well as the possibility of reduced social sup-
port for affected families as the public profile of the condi-
tion shifts from being viewed as an unavoidable
occurrence, to a condition that is understood to be largely
“preventable.” Indeed, the stigma of genetic disease and
the “social policing” of families who have members
affected by screened‐for conditions have been identified as
having a significant and detrimental impact on the mental
and physical well‐being families living with the condition
(Clarke, 2016; Kellog, Slatterly, Hudgins, & Ormond,
2014). Moreover, the lived experiences of these families—
a resource so pivotal to their subsequent reproductive deci-
sion‐making—is set to become increasingly scarce. As the
number of births of affected children declines, so too does
the rich “experiential knowledge” of these families. It is in
this context of dwindling first‐hand experiential resources
that potential parents will come to rely more heavily on the
medical profession for information on the likely prognosis
and daily impact of the conditions identified through
screening programs. Whether or not the medical profession
has adequate insight and resources to be able to offer this
information on the lived experience of genetic diseases,
however, is disputed both within and without the disability
rights community (Farrelly et al, 2012; Williams, Alderson,
& Farsides, 2002).
This paper takes the experiences of people living with
various genetic disabilities as its point of departure in order
to explore attitudes toward genetic intervention in repro-
duction. While the majority of the surrounding literature on
reproductive decisions and attitudes within affected families
have tended to focus on carrier parents (Al‐Jader, Good-
child, & Harper, 1990; Henneman, Kooij, Bouman, &
Kate, 2002; Kelly, 2009; McClaren et al, 2010; Miller &
Schwartz, 1992; Skinner, Sparkman, & Bailey, 2003; Wat-
son, Williamson, & Chapple, 1991), a limited number of
studies have emerged that consider the views of genetically
disabled adults (both physically and cognitively impaired)
toward prenatal diagnosis and selective reproduction. These
studies have produced a complex picture, with some find-
ing support (Chen & Schiffman, 2000; Conway, Allenby,
& Pond, 1994; Janssens et al., 2016), reticence (Barter,
Hastings, Williams, & Huws, 2016; Janssens et al, 2015;
Kelly, 2009), and also ambivalence (Roadhouse et al,
2018; Stern et al, 2002; Taneja, Pandya, Foley, Nicely, &
Arnos, 2004; Ward, Howarth, & Rodgers, 2002) toward
genetic technologies. Despite these limited studies, there
has nevertheless been a general lack of analytic interface
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between the way(s) in which people experience, and assign
value to, their impairment, and how this relates to their
views on genetic carrier screening for it.
By drawing on 43 in‐depth interviews with adults diag-
nosed with one of five highly contrasting genetic disorders,
spinal muscular atrophy (n = 15), thalassemia (n = 8),
hemophilia (n = 9), fragile X disorders (n = 2), or cystic
fibrosis (n = 9), this paper presents a comparative analysis
of the way in which people living with genetic impairment
view the continuing evolution of genomic medicine in the
domain of reproduction, and in particular, their views
toward population‐level preconception and prenatal carrier
screening for the condition they have themselves. In order
to focus on the forms of screening that are most closely
associated with selective reproduction, attitudes toward
newborn genetic screening are not considered.
2 | METHODS
2.1 | Ethical compliance
Ethical approval for the study was granted through the
Biomedical and Scientific Research Ethics Committee
(REGO‐2017‐1910 21/02/2017) and the Health Research
Authority (17/WM/0231 01/08/2017), respectively.
All participants in this study signed a consent form indi-
cating that they had been fully informed about the nature
of the interview, as well as the likely uses of their data. All
names and identifiers were removed during transcription of
the interviews. All names that appear in this paper are
pseudonyms.
2.2 | Methodology
The data drawn on within this paper are derived from two
linked studies. The first (study 1) was a study of the views
of families living with spinal muscular atrophy (SMA)
toward different types of genetic screening, conducted
between 2012 and 2015 (Boardman, Young, & Griffiths,
2017). Fifteen interviews with adults diagnosed with SMA
have been included in this analysis. The second study
(study 2), 2017–2020, involves four additional conditions,
cystic fibrosis, hemophilia, thalassemia, and fragile X syn-
drome. Study 2 data were all collected between March
2017 and March 2018. These four additional genetic condi-
tions were selected for inclusion in study 2 due to their
comparatively high prevalence within the UK population as
well as their contrasting (between conditions) and variable
(within the diagnosis) presentations. Indeed, a broad range
of impairment effects are associated with the five included
conditions: both physical and cognitive/behavioral impair-
ment effects, early‐ and late‐onset symptoms, treatable and
nontreatable conditions, visible and hidden symptoms,
fixed/static disability as well as emerging/degenerative
impairment effects. This range of presentations was deemed
pivotal for a comparative exploration of the relationship
between experiences of the condition and attitudes toward
selective reproduction using preconception or prenatal
screening methods.
Interview participants were recruited primarily through
condition‐specific support groups: SMA Support UK, The
Haemophilia Society, The Fragile X Society, and the Tha-
lassaemia Society. Calls for participants were placed in
each of the groups’ electronic and postal newsletters, web-
sites, and social media accounts (primarily Facebook and
Twitter). Personal visits were also made by the researchers
to the annual patient conferences of SMA Support UK and
the Fragile X Society in order to distribute information
about the study and answer questions about participation.
Two interviews were conducted at both of these patient
conferences.
Due to the preferences of the Cystic Fibrosis Trust, partic-
ipants with cystic fibrosis were all recruited through a large
adult Respiratory Medicine clinic in the north of England,
supported by the Cystic Fibrosis Trust. Fifteen adults with
cystic fibrosis were approached by a research nurse during
routine clinic visits at the center and provided with a partici-
pant information leaflet about the study. Potential partici-
pants were then invited to contact the researcher to ask
questions and/or arrange participation. This sampling tech-
nique leads to the successful recruitment of nine participants.
Interviews were conducted via three principle methods,
face‐to‐face interviews (n = 6), telephone interviews
(n = 19), and email interviews (n = 1). The choice of
interview method was largely determined by the partici-
pant's preferences, abilities, and health status; however, due
to the geographical dispersion of the participants through-
out the United Kingdom, all participants living beyond a
150 mile radius of the University were offered a telephone,
email, or Skype interview only. Face‐to‐face interviews
were carried out at a variety of locations to suit partici-
pants. These included participants’ homes, coffee shops, a
hotel, support group conferences, and a hospital. They
lasted, on average, for approximately 60 min and were
transcribed verbatim with names, place names, and any
other identifiers removed.
The data were analyzed using NVivo 11 qualitative data
analysis software. Open “broad brush” coding of the text
was initially conducted to identify the core meta themes
(e.g., “stories of diagnosis,” “day‐to‐day living,” and so
on), before refinement of the codes was undertaken to
develop more precise subthemes, supported by use of a
hierarchical coding framework. Analysis continued to the
point that “data saturation” had occurred; that is, no new
themes were being added to the coding framework (Glaser,
1967).
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In order to understand the relationship between experi-
ences of genetic disease and attitudes toward genetic carrier
screening, each participant was additionally categorized
according to their degree of support for, or disapproval of,
the introduction of genetic screening programs. The trans-
formation of qualitative data into quantitative categories is
acknowledged as a particularly useful mixed‐methods tech-
nique in order to undertake basic quantitative analysis
(Sandelowski, Voils, & Knafl, 2009). The three categories
used to group all 43 participants were as follows: “supports
selective reproduction,” “nonsupport of selective reproduc-
tion,” or “ambivalence around selective reproduction.” In
order to undertake the categorizations, a previously devel-
oped mixed‐methods technique of data summarizing was
used (Boardman et al, 2011). As participants were asked
directly about their support for screening within their inter-
views, most of the data were contained a particular point in
the transcripts. The summarizing of these data resulted in
43 short summaries, each constituting approximately seven
of eight lines of text. The data summaries were then cate-
gorized. Where categorization was not clear, the partici-
pant's fully coded transcript was returned to, and further
explored, in order to identify supporting contextual data.
This additional exploration occurred for nine participants in
total.
The quotations presented in the paper were selected on
the basis of them particularly eloquently or effectively
illustrating the themes under discussion rather than the con-
ditions per se. As such, no quotations from participants
with fragile X syndrome and hemophilia are included;
however, the perspectives of these participants were instru-
mental in developing the thematic framework of the analy-
sis. Furthermore, the categories “nonsupport of selective
reproduction” and “ambivalent toward selective reproduc-
tion” have been collapsed for the purposes of this analysis
to allow a more focused analysis of the reasons for and
against intervention in reproduction from the perspective of
affected adults.
2.3 | The conditions
In order to contextualize the qualitative data presented
within this paper, it is firstly necessary to understand the
broad implications of each of the conditions for those who
live with them as well as the patterns of their inheritance.
These are outlined below.
2.3.1 | Spinal muscular atrophy
Spinal muscular atrophy (SMA) is an autosomal recessive
inherited neuromuscular condition affecting the lower
motor neurons in the spinal cord, called the “anterior horn
cells” (Sugarman et al, 2012). These cells are vital for
relaying nerve messages between brain and muscle to
enable movement. When a person has SMA, these cells
deteriorate which means that nerve messages cannot be
properly “relayed” between brain and muscle. The person's
muscles then begin to waste or “atrophy” due to lack of
stimulation and use. SMA has a range of clinical presenta-
tions and severities (Markowitz, Singh, & Darras, 2012).
Type I is the most severe form and usually results in infan-
tile death before the age of 18 months. Type II onsets early
in childhood and results in significant disability, although
life expectancy is not greatly curtailed. Type III and IV
SMA usually onset in adult life and generally progress
slowly so that a person is eventually unable to walk. In
2016, the first therapeutic for SMA, Nusinersen, was
approved for use in children with type I (severe) SMA.
This treatment may lessen, rather than completely cure, the
symptoms of SMA.
2.3.2 | Hemophilia
Hemophilia is an inherited bleeding disorder usually caused
by a genetic defect that leads to a deficiency of clotting
factor proteins in the blood (Peyvandi, Garagiola, &
Young, 2016). It is typically inherited in an X‐linked pat-
tern, meaning it is most frequently passed on to men
through the maternal line. The shortage of clotting factors
means that a person with hemophilia bleeds for longer than
usual, and this can be into joints. While hemophilia pre-
dominantly affects men, women may experience a related
form of bleeding disorder known as von Willebrand dis-
ease. The severity of the bleeding disorder depends on the
level of clotting factor an individual has (Den Uijl et al,
2011). Treatment typically involves blood transfusions and
the regular transfusion of clotting factor (prophylaxis). Life
expectancy is generally not affected.
2.3.3 | Thalassemia
Thalassemia refers to a group of inherited blood disorders
that affect hemoglobin. People with the condition produce
either too little or no hemoglobin. This can make them
very anemic, experience delayed growth, osteoporosis, and
reduced fertility (women). There are several forms of tha-
lassemia, which can be divided into alpha and beta types.
Beta thalassemia major is the most severe type. Other types
include beta thalassemia intermedia, alpha thalassemia
major, and hemoglobin H disease (Cousens, Gaff, Metcalfe,
& Delatycki, 2010). People who are a "carrier" of tha-
lassemia, also known as having the thalassemia trait (or
thalassemia minor), typically do not have any serious
health problems themselves, but are at risk of having chil-
dren with the condition. Thalassemia disproportionately
affects people of Mediterranean, South Asian, South‐East
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Asian and Middle Eastern origin (Ryan et al, 2010). Cur-
rently, all pregnant women in the United Kingdom are
offered screening for thalassemia carrier status.
2.3.4 | Cystic fibrosis
Cystic Fibrosis (CF) is an autosomal recessive condition
that primarily affects breathing and digestion. There are
many different gene mutations that cause cystic fibrosis, so
each person with the condition will have different symp-
toms depending on their individual genetic makeup (Castel-
lani et al., 2010). Some people struggle with lung function
and infections, while others need regular enzymes with
every meal to help them digest their food. Many people
with CF will develop CF‐related diabetes in adolescence or
adulthood, and fertility is often affected in men. Many peo-
ple with CF go on to need lung transplantation. Life expec-
tancy for a person with CF today is approximately
47 years (UK Cystic Fibrosis Registry, 2013). A newborn
screening program to identify both babies with CF (and
some carriers of the condition) was introduced in the Uni-
ted Kingdom in 2007.
2.3.5 | Fragile X syndrome
Fragile X syndrome (FXS) is a genetic disorder inherited
in an X‐linked dominant pattern (Hunter et al, 2014).
While not life‐limiting, it is associated with a range of
developmental difficulties, including learning disabilities
and cognitive impairment. In addition, individuals with
FXS may experience anxiety, hyperactive behavior, atten-
tion‐deficit disorder (ADD), features of autism spectrum
disorders, seizures, fertility problems (female), and issues
with social interaction. Usually, men are more severely
affected than women.
While FXS the most common form of the condition,
“fragile X” actually refers to a family of three associated
genetic conditions, depending on whether a person has the
full mutation (resulting in fragile X syndrome) or a premu-
tation (Hantash et al, 2010). People with a premutation
may experience: fragile X tremor‐associated ataxia
(FXTAS) or fragile X‐associated primary ovarian insuffi-
ciency (FXPOI), or be symptomless. Approximately 1 in
151 women carry the FMR1 premutation as do approxi-
mately 1 in 168 men (National Fragile X Foundation,
2018).
3 | RESULTS
3.1 | Participants
Twenty participants were men (44%) and twenty‐five
women (56%), and the majority of the sample (71%) were
of reproductive age (defined as being aged between 15 and
49, in line with World Health Organization definitions) at
the time of their interview (Tables 1–4). A little under half
TABLE 1 Support for selective reproduction among adults with cystic fibrosis
Participant
number
Participant
ID Condition Age Sex
Parental
status
Approves selective
reproduction
Disapproves selective
reproduction
Conflicted selective
reproduction
1 CF002 Cystic
fibrosis
32 M X
2 CF003 Cystic
fibrosis
32 F Parent X
3 CF0004 Cystic
fibrosis
32 F X
4 CF0005 Cystic
fibrosis
58 M Parent X
5 CF0006 Cystic
fibrosis
38 F Parent X
6 CF0009 Cystic
fibrosis
39 F Parent X
7 CF0010 Cystic
fibrosis
28 M X
8 CF0011 Cystic
fibrosis
47 M X
9 CF0012 Cystic
fibrosis
21 F X
10 CF0013 Cystic
fibrosis
30 M X
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of the participants were parents themselves (42%), although
this varied considerably across the disease groups, with the
highest number of parents falling within the hemophilia
group (70%) and the lowest among those diagnosed with
thalassemia (13%). Parental status was relatively similar
across the remaining groups (cystic fibrosis 40%, fragile X
disorders 50%, SMA [all types] 40%). The association of
thalassemia with infertility in women (Skordis, Christou,
Koliou, Pavlides, & Angastiniotis, 1998) and the overrepre-
sentation of women within this group may, at least in part,
account for the significantly lower rates of parenthood
within this group. Similarly, only one male out of the five
with cystic fibrosis was a parent, which may be explained
by the condition's association with male infertility.
Overall, the majority of participants identified as white
British (78%); however, as expected due to the ethnic
prevalence of thalassemia, all eight participants with tha-
lassemia described themselves as being from minority
ethnic backgrounds. Three identified as British Asians (two
as Pakistani and one as Bangladeshi), two as Arabic (one
Iranian and one Lebanese), and the remaining three partici-
pants all described themselves as white European (Italian
and Greek Cypriot).
3.2 | Support for selective reproduction
In total, 17 (38%) of participants in this study reported that
they were in full support of a genetic carrier screening pro-
gram being introduced for the condition they live with,
whether this be a preconception genetic screening program
(PCGS) or a prenatal screening program (PGS). Support
for genetic screening was spread out across the dataset
(cystic fibrosis three participants [30%], fragile X syndrome
one participant [50%], hemophilia one participant [10%],
thalassemia eight participants [100%], and SMA four par-
ticipants [27%]). The most significant contrast was between
TABLE 2 Support for selective reproduction among adults with hemophilia
Participant
number
Participant
ID Condition Age Sex
Parental
status
Approves selective
reproduction
Disapproves selective
reproduction
Conflicted selective
reproduction
1 H001 von Willebrand 66 F Parent
2 H007 von Willebrand 23 F X
3 H008 Von Willebrand 52 F Parent X
4 H0012 Hemophilia A
(severe)
51 M X
5 H0013 Hemophilia A
(severe)
46 M Parent X
6 H0015 Hemophilia A
(moderate)
83 M Parent X
7 H0017 Hemophilia A
(moderate)
57 M Parent X
8 H0018 Hemophilia A
(moderate)
21 M X
9 H0019 Hemophilia A 46 M Parent X
10 H0021 Hemophilia 72 M Parent X
TABLE 3 Support for selective reproduction among adults with thalassemia
Participant
number
Participant
ID Condition Age Sex
Parental
status
Approves selective
reproduction
Disapproves selective
reproduction
Conflicted selective
reproduction
1 TH001 Thalassemia 46 M Parent x
2 TH002 Thalassemia 36 F X
3 TH004 Thalassemia 36 M X
4 TH006 Thalassemia 45 M X
5 TH007 Thalassemia 25 F X
6 TH008 Thalassemia 36 F X
7 TH0012 Thalassemia 44 F X
8 TH0013 Thalassemia 35 F X
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people with hemophilia (where only one person supported
selective reproduction) and thalassemia (where all eight
participants reported that they fully support selective repro-
duction).
Firstly, the accounts of participants who supported
selective reproduction will be presented, before moving on
to those who rejected, or had ambivalent feelings toward it.
The subheadings used reflect the key themes that emerged
under the broader categories of “support” or “nonsupport”
of selective reproduction.
3.2.1 | Support for selective reproduction:
informed choice
For participants who supported selective reproduction,
genetic screening was conceptualized as an important tool,
facilitating informed and responsible parenting decisions.
In a domain of life previously considered to be governed
by “pot luck” or chance, genetic screening was viewed as a
tool through which control and order could be exercised.
Aliya (TH007) is a 25‐year‐old Iranian woman who was
diagnosed with thalassemia major as a young child. Having
come to live in the United Kingdom after her diagnosis,
Aliya's condition has been managed primarily through reg-
ular blood transfusions and medications, enabling her to
live independently and work full‐time. For Aliya, however,
the possibility of choice, control, and informed decision‐
making was critical, particularly for conditions like tha-
lassemia where the burden of treatment remains high and a
cure elusive:
I think in general, knowledge is power‐ the
more you know, the more you are able to
weigh up the risks and benefits of some-
thing..[…]… and if I were given a choice, I
would always choose to have a child without
thalassemia than one with thalassemia….the
ultimate goal [of reproduction], as I see it, is
to have a healthy child, and if it's possible and
doable then I think it's the most responsible
thing you can do as a parent, as a human
being…[…]…a long time ago at the children's
hospital [undergoing blood transfusion] and
there was a mother in the daycare and one
of her children was also having a blood transfu-
sion for thalassemia and she was pregnant with
her next child. And I distinctly remember her
saying you know “what will be will be, it's in
God's hands” and that stuck with me because I
always thought “no, I think we have much
more control now, and we are able to make
conscious decisions as human beings.” I just
thought that attitude was totally irresponsible.
For Aliya, the very availability of genetic technologies
conferred particular responsibilities onto prospective par-
ents and instilled a social expectation that they should exer-
cise them in order to prevent the transmission of genetic
disease at all costs. By minimizing the complex and multi-
factorial decisions associated with genetic screening and
testing to a simple choice between a child with thalassemia
or a child without it, Aliya highlighted her belief in the pri-
oritization of the health of any future children as governing
any reproductive decisions.
3.2.2 | Supporting selective reproduction: the
physical impact of genetic disease
It is noteworthy that all participants who fell into the cate-
gory of supporting genetic screening viewed the condition
they live with as being associated with diminished health
and (often) poor quality of life. Chiara (TH0012) is a 44‐
year‐old woman who was diagnosed with thalassemia in
Sardinia before moving to the United Kingdom at the age
of six. For Chiara, “ignorance” and lack of experience with
the condition being screened or tested for meant that qual-
ity of life is not appropriately factored into reproductive
decisions by would‐be parents to the extent that she felt it
should;
I think there is so much ignorance and that is
why so many children continue to be born
with thalassemia in this day and age, and it's
just not acceptable. You know, I think the
problem is that parents are selfish and thinking
only of their desire to have a child and not
their child itself [if they do not use screening
and selective pregnancy termination].Because
even if thalassemia is nowadays well con-
trolled and we have an open prognosis….it
still takes its toll….you have your freedom but
your freedom is always on a leash….you will
soon need another transfusion. So that's some-
thing that for me has stopped me having kids,
I wouldn't risk to have a child with any type
of disability that will be a burden on their
life…because I know what it means, and if
you don't have a direct experience of that then
you cannot really fully understand.
The vivid contrast that Chiara constructs between her
first‐hand insights into life with genetic disease (“I know
what that means”), and the “ignorance” of parents who
continue to have children with thalassemia irrespective of
this suffering, Chiara was able to assert her perspective and
experiences as an authoritative resource on thalassemia
over the views of such parents and determine the
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boundaries of “acceptable” reproductive behaviors. For
Chiara, only people with thalassemia themselves can fully
appreciate what it means to live with it, and this notion of
privileged knowledge and insight into their condition reoc-
curred across the disease groups, both among those who
objected to, but also those who supported the use of carrier
screening. Beth (CF003), a 32‐year‐old mother of two
young children who has cystic fibrosis herself commented,
“Yeah nobody, I don't care what the doctor says or how
long he's studied for, nobody will ever be able to under-
stand what this experience is like except another CF. We're
the only ones who can make these [reproductive screening]
decisions accurately really.”.
3.2.3 | Support for selective reproduction:
the social impact of genetic disease
However, genetic disease is not experienced in a social
vacuum, and participants within this group, mirroring the
literature, also highlighted the range of social, cultural, and
environmental factors that interfaced with disease severity
to produce particular experiences of it (Miller & Schwartz,
1992). References to stigma, shame, and blame emerged
spontaneously in participants’ accounts (despite them not
being directly asked about within the interview) and were
most prevalent among those who supported genetic screen-
ing, those from ethnic minority groups and those who had
TABLE 4 Support for selective reproduction among adults with spinal muscular atrophy and fragile X
Participant
number
Participant
ID Condition Age Gender
Parental
status
Approves selective
reproduction
Disapproves selective
reproduction
Conflicted selective
reproduction
1 SMA001 SMA type
II
30 F X
2 SMA005 SMA type
II
44 F X
3 SMA009 SMA type
II
25 M X
4 SMA011 SMA type
II
45 M X
5 SMA014 SMA type
II
37 F Parent X
6 SMA020 SMA type
II
34 M X
7 SMA023 SMA type
II
60 F X
8 SMA029 SMA type
II
31 F X
9 SMA007 SMA type
III
47 F Parent X
10 SMA008 SMA type
III
55 M X
11 SMA015 SMA type
III
36 F Parent X
12 SMA021 SMA type
III
38 F Parent X
13 SMA025 SMA type
III
40 F X
14 SMA004 SMA type
IV
45 F Parent X
15 SMA016 SMA type
IV
67 M Parent X
1 FX0013 Fragile X
Syndrome
26 F X
2 FX003 FXTAS 74 F Parent X
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contracted bloodborne viruses in the treatment of their con-
dition (typically hepatitis B/C or HIV). Participants
described being avoided or misunderstood within their
communities (Nathan, H0019, a 46‐year‐old man with
hemophilia), having job offers withdrawn following disclo-
sure of their health status (Sapphira, TH0013, a 35‐year‐old
woman with thalassemia) or being ridiculed or disvalued
for their condition (Jane, SMA023, a 60‐year‐old woman
with type II SMA). Fariha (TH008) is a 36‐year‐old Ban-
gladeshi woman who was diagnosed with thalassemia
shortly after birth. For Fariha, the stigma surrounding her
condition was as significant in creating obstacles in her life
as the condition itself, particularly in the context of
arranged marriages:
The problem is that…..there is a lot of stigma
attached [to thalassaemia] within the South
Asian community and really about people that
had any sort of medical condition really…. I
think because the condition isn't as widely
known in the community, so they just think
“oh she's got a problem, let's not have to deal
with that issue.” So I'd need to sort of notify a
potential partner and their family about it,
they'd have to get tested and it just creates a
lot of issues that they wouldn't have to deal
with with a non‐thalassaemic person. So I
wouldn't be an attractive partner for someone,
I'd be black listed…so to speak. And that goes
for my brother too when he wants to [get mar-
ried] and everyone else related to me‐ we all
go down in value.
Five of the eight participants with thalassemia
described the combined practices of arranged marriages
and consanguineous unions as starkly highlighting the
cultural stigma surrounding genetic disease, a stigma that
extends beyond the diagnosed adult to their wider family
group, typically siblings. While many Middle Eastern
countries (such as Iran, Saudi Arabia) practice compul-
sory premarital genetic screening for prevalent genetic
conditions such as thalassemia, such practices were
described as not “translating” into the Western context
(Aliya), and instead, the responsibility for disclosing
genetic disorders in the family (and particularly for non-
visible conditions) fell squarely on the affected family.
For many participants, this disclosure often resulted in
difficult negotiations.
Sapphira (TH0013) is a 35‐year‐old woman of Greek
Cypriot background. She was diagnosed with thalassemia
as a young child and described feeling very aware (from
childhood) that the genetic status of any future partner was
significant if she wanted children, something that she felt
certain she wanted from a young age. As an adult, how-
ever, Sapphira was already engaged to her (now) husband,
Stefan, before he was screened for thalassemia carrier sta-
tus. When Stefan's test confirmed that he was, in fact, a
carrier of thalassemia (meaning that each pregnancy they
conceive would have a 50% chance of being affected),
Sapphira described her mother urging her to break off the
engagement. At the time of interview, Sapphira and Stefan
were part way through their third and final (NHS funded)
PGD cycle in an attempt to conceive a child without
thalassemia:
I think everyone should have carrier screening
before you get pregnant really so that you can
be made aware beforehand…… before you
even meet the person you want to have chil-
dren with, really, and certainly within the first
year of your relationship so that you can break
it off. Because it's too difficult when you're so
far down the road and you're so invested,
which for us….it was much too late by then,
so we went ahead and got married even
though my mother wasn't happy. I just think it
could save so much heartache and trouble if
people know straight away and then they can
back out [of a relationship] quickly.
For Sapphira who was dedicated to both “eliminating”
thalassemia but who also had religious objections to selec-
tive pregnancy termination, the use of preconception carrier
testing and PGD was the only route to parenthood that she
believed upheld her genetic responsibilities, even in spite
of the intense physical, emotional, and practical burdens
this placed upon her, in terms of the disapproval of her
family, the physical implications of PGD for her health and
the strain on her marriage.
The participants whose accounts have been presented
within this section largely viewed genetic disease as a bur-
den upon the life of the affected individual, and their fam-
ily as well as wider society. This was both in terms of
quality of life but also the social implications of stigma
and responsibility. However, not all participants viewed
genetic disease this way. Indeed, the vast majority
expressed ambivalent or negative views about the possibil-
ity of screening, accounts that will now be turned to.
3.3 | Nonsupport or ambivalence toward
selective reproduction
In total, 28 participants (65% of sample) reported concerns
or objections about the introduction of genetic screening
for the condition they live with. The reasons for these atti-
tudes were complex and nuanced, drawing on a rich array
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of resources, primarily their lived experiences of genetic
disease (Boardman, 2014a).
3.3.1 | Nonsupport for selective reproduction:
valuing life affected by genetic disease
Indeed, the most common reason for screening rejection
within this group related to a perceived mismatch between
the way in which society views and values their genetic
impairment in comparison with the way in which they
actually experienced it in their lives.
Seth (CF002) is a 32‐year‐old man, diagnosed with cys-
tic fibrosis (CF) at the age of two. Seth works part‐time as
a doctor in a busy inner‐city hospital, a schedule which
allows him time to physically recover from his shifts and
also to manage his medication regimen. While Seth
described CF as placing some limitations on his life, “I
wouldn't say it reduces my quality of life, but I would say
it affects my ability to take advantage of life,” he was very
clear that he saw a contradiction between championing and
affirming the lives of people with CF (including his own),
“I think attitude is everything and we have to be positive
about what people with CF can offer,” while also lending
support to genetic screening, a practice which he acknowl-
edged could have prevented his existence;
I can understand why somebody might want to
find out whether their child was likely to have a
genetic disease or an inherited malformation…
such as Down's Syndrome [sic], but I struggle
to…if it were me, to use that information to
make a decision about whether or not to proceed
with a pregnancy. But again I do think Down's
syndrome [sic] in a kid would be much harder to
deal with than CF….but it's just too close to
home and too hypocritical for me to think it's ok
to abort someone with one condition when I've
also got a condition you can screen for and that
is genetically inherited because that then opens
the door to someone aborting me, or someone
else with CF. …I just couldn't choose to abort a
child based on the presence or absence of
genetic disease because with that you're imply-
ing that one life is more worthy than another
because of their genetics and that's an idea I
can't get on board with….obviously.
Developed initially as a way to describe a particular
response to prenatal testing and selective termination, the
“expressivist objection”; that is, the idea that the practices
of selective reproduction expresses disvalue of people with
disabilities (Boardman, 2014b, 2014a; Parens & Asch,
2000) was frequently alluded to by people with different
genetic conditions. For Seth, the practice of screening and
the concomitant offer of pregnancy termination merged the
diagnostic boundaries between screened‐for conditions.
Down syndrome and cystic fibrosis became amalgamated
in Seth's response as all “screened‐for conditions,” which
meant that a termination for Down syndrome had impli-
cations for himself and other people with “detectable”
disorders.
3.3.2 | Nonsupport of selective reproduction:
identity politics of genetic disease
While it has been argued that the practices of selective
reproduction reduce the genetically disabled fetus from
being a “potential person” to a single genetic trait—that is,
the disabling condition (Parens & Asch, 2000), participants
in this study were keen to separate out the traits and char-
acteristics they saw as comprising the personality of the
person, from the condition that disables them. Henry
(CF005) is a 58‐year‐old man who has lived with cystic
fibrosis since infancy. While his condition rendered him
infertile, Henry and his wife conceived a daughter through
the use of donor gametes. For Henry, the use of a donor
meant that he could be sure his daughter would not be a
carrier of cystic fibrosis, “It's important for me that she
don't have to worry about this stuff when it comes to her
turn [to have children].” For while he would like to see a
decline in the disease, he was ambivalent about genetic
screening as being the means to achieve this.
In an ideal world, ok, no, you wouldn't want
CF, so if they could get rid of CF through
maybe gene therapy or drug therapy, then I
think that would be great. But I just think peo-
ple with CF have an awful lot to give…it's
just a disability at the end of the day, it
doesn't dictate how your whole life's going to
be. Terminating CF babies would be just such
a huge loss because who knows what them
babies were going to bring? You know, eradi-
cating CF is fantastic, but just not at the
expense of abortions. Not at this price.
By recognizing that CF is merely one part of his life
and not the whole, and just one part out of all the informa-
tion there is to know about a fetus, Henry focused his cri-
tique of selective reproduction on its reductionism (i.e., the
practice of valuing the fetus only as a CF fetus) rather than
the nature (positive or negative) of that valuation per se.
For Henry, CF remained a “cruel disease” a condition that
“robbed” people of life and life opportunities, and conse-
quently, he had few reservations about eradicating it. For
him, selective reproduction is problematic not because it
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has the potential to reduce the incidence of CF, but because
it does so by simultaneously eradicating those fetuses who
would become people with CF.
3.3.3 | Nonsupport for selective reproduction:
genetic disease as privileged state
Unlike Henry, however, some participants viewed their
impairment in a far more positive light, as a uniquely valu-
able and integral part of their personhood. Sasha
(SMA001) is a 30‐year‐old woman who was diagnosed
with SMA type II at the age of 20 months. She never
developed the ability to walk and has been using a pow-
ered wheelchair since the age of 4. Sasha works full‐time
as a teaching assistant and lives independently with the
support of personal assistants. Sasha described SMA as
having given her a unique perspective on life that would
otherwise have been inaccessible to her:
I just can't imagine my life without it [SMA],
it's not only who I am, it's what I am. It's part
of everything I do, from work, how I live
what I dress like. And this is why screening
for me is a no‐go for me personally, because I
wouldn't have wanted to not come into the
world just because of SMA and I wouldn't
want someone making that decision for me.
Because actually, it [SMA] gives me a unique
perspective. It makes me relate to people on a
level I just couldn't have done [without it]. I
have insight, I suppose, into parts of human
experience that no one in a million years…. I
just think if someone said tomorrow “here's a
cure,” you know, I would have to think very
carefully about taking that, as odd as that
sounds. And actually, I really don't know if I
would.
It is noteworthy that all participants with SMA type II,
a condition which is relatively static from birth, were more
likely than those participants with degenerative forms of
SMA (type IV or adult‐onset), or with a condition involv-
ing periods of ill health (such as CF) to express ambiva-
lence or disapproval of selective reproduction. Shakespeare
(2006), among others, Livneh and Antonak (2005), Board-
man et al (2017), and Watson (2010), together with anec-
dotal accounts (Albers, 2018), have highlighted that
personal identification with one's impairment is critical to
the formulation of attitudes toward cure and elimination of
disability. Those who remember their lives as an able‐bod-
ied person or who experience periods of illness are likely
to have very different views of their condition than people
with fixed impairments (Boardman et al, 2017;
Shakespeare, 2006), and these data confirm previous stud-
ies that this valuing of genetic impairment translates not
only into attitudes toward cure, but also attitudes toward
selective reproduction given that both are directed toward
the goal of amelioration of genetic disease, albeit through
very different approaches.
3.3.4 | Nonsupport of selective reproduction:
the social construction of genetic disability
While difficulties associated with the stigma of genetic dis-
ease emerged as a key reason why selective reproduction
was supported by participants in this study, it is noteworthy
that it also appeared within justifications of the nonsupport
of screening and selective pregnancy termination. While
stigma was not specifically asked about within the inter-
view schedule for this study, references to it nevertheless
emerged spontaneously across the dataset both for those
who supported selective reproduction, but also those who
did not, highlighting the complexity of the relationship
between genetic disease and stigma.
For participants who were uncomfortable with the prac-
tices of selective reproduction, stigma was no less prevalent
than for those who supported it; however, for this group of
participants, the existence of stigma underscored the social
construction of genetic disease. Jonathan (SMA0011) is a
45‐year‐old man with type II SMA. He lives independently
with the assistance of PAs and works as an accountant for
his family's business. Jonathan was diagnosed with SMA
shortly after birth following the diagnosis of his older
brother, Lee (also with type II SMA) aged 18 months. For
Jonathan, stigma was as much a part of his experience of
genetic disease his impairment:
I honestly do think that 97% of the problems
that I have in my day‐to‐day life are down to
other people's attitudes than actually the SMA
itself. I can manage the SMA, that's a piece of
cake, but what we can't get away from the fact
that we live in a society that views disabled
people in a particularly negative way, excludes
them and treats them as something to fear and
avoid. So, no, I don't think abortion is the
answer because you're making the disabled
baby pay with its life the price for society's
problem, actually…. So really if you think
about it, the cure doesn't match the ailment
does it?
By distinguishing between the biological domain of his
impairment (the SMA) and its social consequence (his
resulting disability), Jonathan, in line with social model of
disability theorizing, suggested that social and political
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efforts to improve the lives of disabled people should
invariably focus on latter rather than the former (de Wolfe,
2002). Selective termination was viewed by Jonathan as an
entirely inappropriate response to what he saw as a primar-
ily social issue. Indeed, a preference that funding invested
in the implementation of genetic screening programs would
be better spent on removing social, physical, and environ-
mental barriers for disabled people was also mentioned by
seven other participants within this group.
However, not all participants viewed their impairment
through the prism of social model thinking and many
instead highlighted the components of their impairment
experience (typically pain, anxiety feeling unwell, uncon-
trolled bleeding) as being unamenable to social amelioration
(de Wolfe, 2002). This is not to say that these participants
did not place a high value on dismantling social barriers,
but rather that they viewed particular aspects of their
impairment experience as existing beyond their social
construction of them. Furthermore, they viewed them as
experiences for which an entirely inclusive and accessible
society could not prevent, a caveat that some social model
of disability theorists have more recently acknowledged
(Shakespeare, 2006). While for many this could lead to neg-
ative, complex, or ambivalent attitudes toward the condition
they live with (e.g., Henry), the data presented in this
section highlight that, nevertheless, support and enthusiasm
for selective reproduction remained a nonsequitur.
4 | DISCUSSION
This paper is, to the best of our knowledge, the largest
qualitative study of the views of people living with differ-
ent types of genetic impairment toward the practice of
selective reproduction. The literature has produced a some-
what contradictory picture of the views of this group of
people, with some highlighting widespread support for
genetic screening and testing (Chen & Schiffman, 2000)
while others revealing more ambivalent views (Gollust,
Thompson, Gooding, & Biesecker, 2003). This study high-
lights the complexity of the attitudes of genetically disabled
adults and higher rates of ambivalence and negative atti-
tudes than has previously been reported. As the capabilities
of genomic technologies continue to evolve, the list of con-
ditions they are capable of detecting in the preconceptual
and prenatal period are expanding accordingly (Nuffield
Council on Bioethics, 2018). It is within this context that
the views of people living with “detectable” genetic dis-
eases are set to become increasingly significant. Indeed,
people living with genetic disorders are set to be dramati-
cally impacted by the introduction of selective reproductive
for their disease and its transformation into a “screened‐
for” (and therefore potentially preventable) condition.
Moreover, in the context of a strained NHS service,
negative public attitudes toward conditions for which a per-
son is deemed to have (wholly or in part) contributed to
(such as obesity, type II diabetes, or smoking‐related dis-
eases) highlight the significance of notions of personal
accountability for one's health (Boardman et al, 2011). For
individuals and their families living with genetic disease,
the very availability of new methods of selective reproduc-
tion suggests new forms of “genetic responsibility” and
accountability for decisions that previously did not exist
(Hallowell, 2001).
As suggested by previous work with adults with genetic
impairments, the data generated by this study highlight the
significance of the way life with genetic disease is valued
in determining attitudes toward selective termination (Gol-
lust et al, 2003). As disabled people frequently rate the
quality of their lives more highly than evaluations made by
nondisabled people of them (Vimerö & Krause, 1998), it is
perhaps somewhat unsurprising that the vast majority of
participants within this sample expressed negative attitudes
or ambivalence toward the genetic manipulation of repro-
duction. However, by including a range of disease groups,
the data also highlight the plethora of factors that influence
the degree to which a disabled person views their impair-
ment positively. These include the social, environmental,
cultural, and religious context, but also the degree to which
a condition is internalized and regarded as a part of a per-
son's identity (Watson, 2010).
The internalization of a disabled identity is a complex
phenomenon, incorporating the nature, onset, and duration
of lived experience of the condition (Boardman et al, 2017)
as well as the way in which perceptions of the condition
are reflected back to individuals through their encounters
with the social world. Those participants who most
ardently supported selective reproduction typically high-
lighted the negative nature of their impairment experiences
(often describing periods of illness, pain, fatigue, and suf-
fering) and the detrimental impact their condition had on
their life, most commonly in terms of restricted life oppor-
tunities (most commonly in the domains of relationships,
work, and housing) as well as lack of social, financial, and
practical support. Intensive treatment regimes, particularly
for those with CF and thalassemia, were also presented as
prohibitive of a full and successful life in and of them-
selves as Chiara, a woman with thalassemia commented,
“your freedom is always on a leash” (Chiara). It is notable
that the stigma of genetic disease was also discussed more
frequently by the 17 participants who supported selective
reproduction than those who did not. This stigma was
expressed in a variety of ways, as fear and avoidance of
the affected person, but also as a reduction in status and
prestige for those originating from communities within
which arranged marriages and the integrity of bloodlines
were highly valued. Indeed, it is noteworthy that all eight
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participants diagnosed with thalassemia (all from minority
ethnic backgrounds) were in support of selective reproduc-
tion and three of these eight participants even argued that
the prevention of future lives affected by thalassemia
should be mandatory.
By separating out their sense of personal identity and
self from their (negatively valued) genetic condition, these
17 participants could present selective reproduction as a
straightforward decision between a disabled and an able‐
bodied child. As one participant, Natasha (SMA004), a 45‐
year‐old woman with type III SMA commented, “…it boils
down to you having to choose your baby with SMA or
without SMA, so I can't understand anyone choosing to let
them keep the SMA.” This distinction is something of a
misnomer given that—in the absence of a cure—a fetus
and their genetic disorder cannot be, biologically speaking,
separated out (thus, selecting against a genetically disabled
fetus also means selecting against that particular fetus and
replacing it with another, nondisabled fetus). However, by
viewing their condition as something extrinsic to them-
selves, participants such as Natasha were able to navigate,
and minimize, these more emotionally challenging parts of
selective reproduction, including the expressive potential of
reprogenetic decisions (Boardman, 2014a; Edwards, 2004).
For the majority of the sample, however, genetic disease
was presented as being more deeply interwoven with per-
sonal identity—even for those who viewed their condition
negatively (Henry). Selective reproduction was critiqued by
these participants for its privileging of specific pieces of
genetic information to determine the value of a whole indi-
vidual, a tension that was easily recognizable for many par-
ticipants given their broader experiences with disablism
and stigma in everyday society.
This way of responding to genetic disease and selective
reproduction allowed for more nuanced interpretations of
participants’ lived experience. While for participants who
supported selective reproduction, their condition could not
be presented as anything other than a negative and invasive
experience, for those whose condition was characterized as
an integral part of their identity and sense of self, there
was more room to interpret its impact in shifting and three‐
dimensional ways. While Henry, like many of the partici-
pants who supported selective reproduction, described his
lived experience of CF as often difficult and negative, by
presenting it as an indelible part of his identity and daily
life, his calculation of the costs of selective reproduction
was markedly different from those of people who also neg-
atively evaluated their condition, but identified with it in
entirely different ways. .
As the empire of genomic medicine continues to expand
and the voices of people with genetic disabilities become
an increasingly scarce resource (Bricher, 1998), a sustained
and in‐depth consideration of their views toward selective
reproduction is now of critical importance (Nuffield Coun-
cil on Bioethics, 2018; Scully, 2008). By exploring the per-
spectives of 45 people living with five very different
genetic disorders, this study emphasizes that support for
genetic intervention in reproduction is not universal among
people living directly with the conditions that the technolo-
gies are targeted to prevent. Both support and nonsupport
of selective reproduction hinged on the value each partici-
pant assigned to their quality of life and that which they
assigned to others with the same condition. However, this
study also highlights that this process of ascribing value
was not a straightforward process whereby negative views
of the condition necessarily implied support for selective
reproduction. Rather, these judgments were thoroughly
mediated by participants’ sense of their own self and per-
sonal identity and the position their condition occupied
within this formulation. While the nature and type of
impairment experiences participants reported had a signifi-
cant and complex role to play within this calibration
(Boardman et al, 2017), the data also highlight the signifi-
cance of social and cultural factors in the way in which
genetic impairments were internalized and valued, most
notably the experiences of stigma and social support.
These findings suggest that even though notions of
(medically defined) disease severity and quality of life are
the concepts that continue to dominate policy discussions
surrounding which conditions should (and which should
not) be included on genetic screening panels (Korngiebel
et al., 2016; Lazarin et al, 2014; Leo et al., 2016), that
such stakeholder debates might more usefully attend to the
complexity of disability identity politics and the social and
cultural experiences of genetically disabled people (includ-
ing that of stigma). If people with genetic impairments are
to be meaningfully engaged in these debates, their relation-
ship to their impairment is an important point of departure
(Bricher, 1998). As this study highlights, it was not possi-
ble to “read off” participant attitudes toward selective
reproduction by reference only to the nature and severity of
their impairment. Genetic impairment is always experi-
enced within a specific social, cultural, and environmental
milieu which can be as significant in determining quality
of life and reproductive attitudes for genetically disabled
people as the condition itself.
4.1 | Strengths and weaknesses
By including five different genetic conditions and utilizing
a range of recruitment processes (including both clinics and
support groups), this study offers an expansive view of the
range of attitudes toward selective reproduction among
people with genetic diseases. The data may be somewhat
limited by the reliance on support group recruitment for
participants with fragile X, hemophilia, thalassemia, and
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SMA; however, there were no marked differences in the
responses between these groups and participants with cystic
fibrosis, all of whom were recruited through an adult respi-
ratory clinic. This suggests that the recruitment strategy did
not significantly bias the findings.
Men with fragile X syndrome, who are generally con-
sidered to be most severely affected of all the fragile X dis-
orders, are also missing from the sample. While attempts
were made to recruit such participants for interview (typi-
cally after their parent had been interviewed), the degree of
learning disability associated with fragile X syndrome was
often described by parents as a barrier to their participation.
While other research has successfully engaged adults with
learning disabilities into research on selective reproduction
(Barter et al, 2016; Ward et al, 2002), this perspective is
missing from this study. Similarly, people with type I
SMA (the most severe form) are absent from the sample
due to the very poor prognosis associated with this form of
the disorder. It is possible that the exclusion of these most
severely affected individuals may have influenced the study
findings. However, in spite of these limitations, the final
sample nevertheless included a wide spectrum of disease
presentations and severities, and, accordingly, also a broad
range of perspectives on genetic screening.
5 | FURTHER RESEARCH
Future research may usefully explore the way in which the
development of gene therapies and genome editing influ-
ences the intersection of disability, impairment, and identity
for people with genetic diseases. By obviating the per-
ceived need for selective pregnancy termination, the possi-
bility of gene therapy and/or genome editing is set to
dramatically alter the landscape and purpose of selective
reproduction. Research exploring what these developments
mean for and to disabled people themselves will open up
important lines of enquiry both within and beyond the
selective reproduction debate.
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